{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.7","upperLimit":"78.8","value":"44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Percentage of patients experiencing grade 3 or higher adverse events will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive larotrectinib sulfate PO or via NG- or G-tube BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo a CT scan, MRI, an x-ray, bone scan, and/or MIBG scintigraphy during screening and on study. Patients also undergo bone marrow aspiration and/or biopsy during screening and may undergo blood sample collection on study.","id":"OG000","title":"Treatment (Larotrectinib Sulfate)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study entry","title":"Percentage of Patients Experiencing Grade 3 or Higher Adverse Events","type":"SECONDARY","unitOfMeasure":"percentage of participants"}